PHS
ALXN

PFM Health Sciences’s Alexion Pharmaceuticals ALXN Stock Holding History

PFM Health Sciences’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-901,441
Closed -$166M – 103
2021
Q2 		$166M Sell
901,441
-158,190
-15% -$27.2M 5.19% 1
2021
Q1 		$162M Buy
1,059,631
+78,500
+8% +$12.1M 4.95% 3
2020
Q4 		$153M Buy
981,131
+277,314
+39% +$35.6M 5.39% 1
2020
Q3 		$80.5M Buy
703,817
+24,933
+4% +$2.69M 3.72% 5
2020
Q2 		$76.2M Sell
678,884
-7,365
-1% -$782K 3.95% 2
2020
Q1 		$61.6M Sell
686,249
-390,193
-36% -$38.3M 5.06% 1
2019
Q4 		$116M Sell
1,076,442
-370,170
-26% -$39.6M 5.55% 2
2019
Q3 		$142M Buy
+1,446,612
New +$163M 4.18% 3
2017
Q1 		– Sell
-133,605
Closed -$16.3M – 126
2016
Q4 		$16.3M Buy
+133,605
New +$16.3M 0.46% 63
2015
Q1 		– Sell
-70,987
Closed -$13.1M – 105
2014
Q4 		$13.1M Buy
+70,987
New +$13.2M 0.31% 71

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

PFM Health Sciences's ALXN Position: Q3 2021 in Review

PFM Health Sciences sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 901,441 shares — an estimated $166M sold.

PFM Health Sciences first reported a position in ALXN in Q4 2014 and held it in 10 quarters. The position peaked at $166M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • PFM Health Sciences reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • PFM Health Sciences sold 901,441 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
  • PFM Health Sciences first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 10 quarters.
  • PFM Health Sciences's Alexion Pharmaceuticals position peaked at $166M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.